Insights & news

Belgium Takes Final Steps to Formalise Cooperation with Luxembourg on Surveillance of Medicines and Health Products

  • 04/01/2023
  • News

On 27 December 2022, the Belgian Official Journal published a Law of 7 November 2022 giving assent to the Cooperation Treaty between the Kingdom of Belgium and the Grand Duchy of Luxembourg regarding Medicines and Health Products, as signed in Luxembourg on 17 January 2018 (the Treaty) (Wet van 7 november 2022 houdende instemming met het Samenwerkingsverdrag tussen het Koninkrijk België en het Groothertogdom Luxemburg inzake geneesmiddelen en gezondheidsproducten, gedaan te Luxemburg op 17 januari 2018/Loi du 7 novembre 2022 portant assentiment à la Convention de coopération entre le Royaume de Belgique et le Grand-Duché de Luxembourg en matière de médicaments et de produits de santé, faite à Luxembourg le 17 janvier 2018 – the Law). The Law is accompanied by the text of the Treaty, which, according to the Law, entered into force on 28 November 2022 (see, attached copy).
The Treaty intends to regulate cooperation between Belgium and Luxembourg in the fields of medicines, medical devices and blood, cells and tissues of human origin. Its main purpose is to allow for the participation of Belgian inspectors in inspections in Luxembourg to monitor compliance with the applicable regulatory framework, including Good Manufacturing Practices (GMP) and Good Distribution Practices, until Luxembourg will be able to deploy own inspectors for these purposes. Until recently, Luxembourg did not have its own GMP inspectors as there was no medicines manufacturing activity on its territory. The country’s decision to establish a national medicines agency that is separate from the executive branch of government is as recent as December 2019 (see, Van Bael & Bellis Life Sciences News and Insights of 6 January 2020).
While the Law was adopted by the Chamber of Representatives on 28 April 2022, it took until 7 November 2022 for it to be promulgated by the King. Moreover, the Law’s subsequent publication in the Belgian Official Journal did not happen until 27 December 2022. We are unsure about the reasons for this drawn-out process.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 25/01/2023
    • News

    Belgian and Dutch Competition Authorities Aim Again at Pharmaceutical Sector

    As if on cue, the Belgian and Dutch competition authorities announced on 24 January 2023 new significant developments with regard to their enforcement activities in the pharmaceutical sector

    Read more
    • 23/12/2022
    • News

    Court of Justice of European Union Clarifies Advertising Rules for Medicinal Products Not Subject to Medical Prescription or Reimbursement

    On 22 December 2022, the Court of Justice of the European Union delivered a judgment in response to a reference for a preliminary ruling from the Constitutional Court of Latvia, concerning the application of Directive 2001/83/EC on the Community code relating to medicinal products for human use (the Directive). The judgment clarifies that the concept of “advertising of medicinal products” within the meaning of the Directive not only covers the advertising of a specific medicinal product, but also extends to advertisement campaigns for categories of medicines by pharmacies. The judgment also holds that Member States are not precluded from prohibiting advertisements of a type not listed in Article 90 of the Directive, if the aim of the national measure is to safeguard public health by discouraging irrational use.

    Read more
    • 14/12/2022
    • News

    Lithuanian Competition Authority Fines Pharmacy Association and Individual Firms for Collusion while Participating in Margin-setting Procedure

    According to the attached press release of yesterday’s date, the Lithuanian competition authority (Konkurencijos Taryba or KT) levied total fines of more than EUR 72 million on the Lithuanian Pharmacy Association and 8 individual pharmaceutical companies. While KT imposed a record fine, the allegedly cartel-like conduct that prompted the fine is unusual and raises delicate questions regarding the borderline between legitimate collective advocacy and illegitimate collusive behaviour. The public version of the actual decision of KT and the judgment on appeal which the Regional Administrative Court of Vilnius is expected to deliver will hopefully clarify the dividing line between these two types of conduct.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *